id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-348987-3jpdvy7n	Annangi, Srinadh	Chloroquine and hydroxychloroquine for COVID‐19: A word of caution	2020-05-11		.txt	text/plain	844	51	50	1 Prior research including with human immunodeficiency virus (HIV) and SARS-CoV-1 has shown that in vitro antiviral activity of CQ and HCQ does not necessarily translate to in vivo clinical efficacy. 3 It is unclear how the differences in the EC 50 values will impact the in vivo prophylactic antiviral efficacy at their recommended doses of HCQ 400 mg twice daily (bd) on day 1 and then 200 mg bd for 5 days. Until then, CQ and HCQ should only be used in the setting of clinical trials with a clear understanding among physicians and patients of uncertain efficacy and potentially harmful side effects. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial	./cache/cord-348987-3jpdvy7n.txt	./txt/cord-348987-3jpdvy7n.txt